|
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
|
Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis. |
Jan 2019 |
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
|
Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. |
Jan 2019 |
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
|
Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia |
Jul 2020 |
Critical reviews in hematology/oncology |
Myelodysplastic Syndromes (MDS) |
|
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS |
Jun 2019 |
Current Hematologic Malignancy Report |
Myelodysplastic Syndromes (MDS) |
|
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
Apr 2023 |
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
|
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities |
Apr 2024 |
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
|
Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials |
May 2024 |
Current Medical Research and Opinion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Germline mutations in MDS/AML predisposition disorders |
Mar 2021 |
Current opinion in hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes |
May 2023 |
Current Treatment Options in Oncology |
Myelodysplastic Syndromes (MDS) |
